These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30097256)

  • 21. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
    Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
    Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased risk of severe infections in non-small-cell lung cancer patients treated with pemetrexed: a meta-analysis of randomized controlled trials.
    Tong S; Fan K; Jiang K; Zhai W; Fang B; Wang SH; Wang JJ
    Curr Med Res Opin; 2017 Jan; 33(1):31-37. PubMed ID: 27590399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.
    Paz-Ares LG; Zimmermann A; Ciuleanu T; Bunn PA; Antonio BS; Denne J; Iturria N; John W; Scagliotti GV
    Lung Cancer; 2017 Feb; 104():45-51. PubMed ID: 28212999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer.
    Kim YS; Cho EK; Woo HS; Hong J; Ahn HK; Park I; Sym SJ; Kyung SY; Kang SM; Park JW; Jeong SH; Park J; Lee JH; Shin DB
    Cancer Res Treat; 2016 Jan; 48(1):80-7. PubMed ID: 25761488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceritinib versus chemotherapy in ALK-positive lung cancer.
    Marshall H
    Lancet Respir Med; 2016 Dec; 4(12):952-953. PubMed ID: 27838332
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.
    Jo J; Kim SH; Kim YJ; Lee J; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Chung JH; Jeon YK; Lee JS
    Yonsei Med J; 2018 Mar; 59(2):202-210. PubMed ID: 29436187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.
    Patel JD; Paz-Ares L; Zinner RG; Barlesi F; Koustenis AG; Obasaju CK
    Clin Lung Cancer; 2018 Nov; 19(6):e823-e830. PubMed ID: 30369427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.
    Cazzaniga ME; Camerini A; Addeo R; Nolè F; Munzone E; Collovà E; Del Conte A; Mencoboni M; Papaldo P; Pasini F; Saracchini S; Bocci G
    Future Oncol; 2016 Feb; 12(3):373-87. PubMed ID: 26584409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of pemetrexed for non-small cell lung cancer in the Andalusian public health system.
    Pérez-Moreno MA; Cotrina-Luque J; Galván-Banqueri M; Flores-Moreno S; Bautista-Paloma FJ; Calleja-Hernández MÁ
    J Chemother; 2015; 27(6):371-7. PubMed ID: 25971603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale and Design of PEMVITASTART-An Open-label Randomized Trial Comparing Simultaneous Versus Standard Initiation of Vitamin B
    Baldi M; Behera D; Kaur J; Kapoor R; Singh N
    Clin Lung Cancer; 2017 Jul; 18(4):432-435. PubMed ID: 28073680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed.
    Park S; Kim HJ; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Choi SH; Rho JK; Lee JC
    BMC Cancer; 2016 Jul; 16():417. PubMed ID: 27388008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer.
    Rossi G; Alama A; Genova C; Rijavec E; Tagliamento M; Biello F; Coco S; Dal Bello MG; Boccardo S; Grossi F
    Expert Opin Pharmacother; 2018 Dec; 19(17):1969-1976. PubMed ID: 30354693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous non-small-cell lung cancer in Spain.
    González García J; Gutiérrez Nicolás F; Nazco Casariego GJ; Valcárcel Nazco C; Batista López JN; Oramas Rodríguez J
    Farm Hosp; 2017 Jan; 41(n01):3-13. PubMed ID: 28045649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2.
    Schluckebier L; Garay OU; Zukin M; Ferreira CG
    Lung Cancer; 2015 Sep; 89(3):274-9. PubMed ID: 26143106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer.
    Igawa S; Sasaki J; Otani S; Shirasawa M; Niwa H; Kusuhara S; Harada S; Kubota M; Katagiri M; Masuda N
    Oncology; 2016; 91(1):41-7. PubMed ID: 27234033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.
    Svaton M; Fiala O; Pesek M; Bortlicek Z; Minarik M; Benesova L; Topolcan O
    Anticancer Res; 2016 Mar; 36(3):1077-82. PubMed ID: 26977001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
    Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
    Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy and Toxicity of Metronomic Oral Vinorelbinen in Advanced Non-small Cell Lung Cancer after Failure to Multiple-lines Treatments].
    Yao S; Gu Y; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):737-740. PubMed ID: 29167002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
    Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
    Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.